246 related articles for article (PubMed ID: 26575017)
1. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A.
Hung MH; Wang CY; Chen YL; Chu PY; Hsiao YJ; Tai WT; Chao TT; Yu HC; Shiau CW; Chen KF
Oncotarget; 2016 Jan; 7(1):638-55. PubMed ID: 26575017
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer.
Liu H; Gu Y; Wang H; Yin J; Zheng G; Zhang Z; Lu M; Wang C; He Z
Oncotarget; 2015 Jun; 6(17):14913-25. PubMed ID: 25945834
[TBL] [Abstract][Full Text] [Related]
3. Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation.
Huang CY; Hung MH; Shih CT; Hsieh FS; Kuo CW; Tsai MH; Chang SS; Hsiao YJ; Chen LJ; Chao TI; Chen KF
J Pharmacol Exp Ther; 2018 Sep; 366(3):410-421. PubMed ID: 29914877
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
Hung MH; Chen YL; Chu PY; Shih CT; Yu HC; Tai WT; Shiau CW; Chen KF
Oncogene; 2016 Sep; 35(37):4891-902. PubMed ID: 26876205
[TBL] [Abstract][Full Text] [Related]
5. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X
Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251
[TBL] [Abstract][Full Text] [Related]
7. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
8. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
[TBL] [Abstract][Full Text] [Related]
9. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
10. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET - PP2A Signaling axis.
Hu X; Garcia C; Fazli L; Gleave M; Vitek MP; Jansen M; Christensen D; Mulholland DJ
Sci Rep; 2015 Nov; 5():15182. PubMed ID: 26563471
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel resistance in MCF-7/PTX cells is reversed by paeonol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway.
Zhang W; Cai J; Chen S; Zheng X; Hu S; Dong W; Lu J; Xing J; Dong Y
Mol Med Rep; 2015 Jul; 12(1):1506-14. PubMed ID: 25760096
[TBL] [Abstract][Full Text] [Related]
13. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
Klimaszewska-Wiśniewska A; Hałas-Wiśniewska M; Grzanka A; Grzanka D
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495431
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Zhang XH; Shin JY; Kim JO; Oh JE; Yoon SA; Jung CK; Kang JH
Cancer Lett; 2012 Sep; 322(2):213-22. PubMed ID: 22433711
[TBL] [Abstract][Full Text] [Related]
16. miR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC).
Ye J; Zhang Z; Sun L; Fang Y; Xu X; Zhou G
Mol Biosyst; 2016 Oct; 12(11):3417-3424. PubMed ID: 27714074
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
18. Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Li S; Liu Z; Zhu F; Fan X; Wu X; Zhao H; Jiang L
Oncol Res; 2013; 21(3):137-44. PubMed ID: 24512728
[TBL] [Abstract][Full Text] [Related]
19. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
[TBL] [Abstract][Full Text] [Related]
20. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]